← Back to CJC-1295 + Ipamorelin product page
Identification of CJC-1295 as a Long-Lasting GHRH Analog
A 2005 study published in Endocrinology described the identification of CJC-1295 as a long-lasting growth hormone-releasing factor analog. Researchers developed a series of human GRF(1-29)-albumin bioconjugates and evaluated their ability to activate the GRF receptor on the anterior pituitary in rat models. The study aimed to identify GHRH analogs with extended plasma half-lives while retaining full biological activity at the GHRH receptor.
CJC-1295, a tetrasubstituted form of hGRF(1-29) with an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C terminus, was found to bind covalently to endogenous albumin after injection, dramatically extending its plasma half-life. In rat models, CJC-1295 was detected in plasma beyond 72 hours and stimulated GH secretion for an extended period compared to unmodified GRF(1-29). The “no DAC” form (Modified GRF 1-29) retains the four amino acid substitutions for stability but lacks the albumin-binding moiety, resulting in a shorter-acting profile suitable for pulsatile GH release research.
Citation: Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PubMed PMID: 15817669
Sustained GH and IGF-I Secretion Following CJC-1295 Administration
A study published in the Journal of Clinical Endocrinology & Metabolism (2006) evaluated the pharmacodynamics of CJC-1295 on GH and insulin-like growth factor I (IGF-I) secretion. Subcutaneous administration resulted in sustained, dose-dependent increases in both GH and IGF-I levels. The GH secretory response maintained its physiological pulsatile pattern despite continuous receptor stimulation.
The finding that pulsatile GH secretion persisted during CJC-1295 stimulation was mechanistically important. It demonstrated that GHRH receptor stimulation does not override the endogenous somatostatin-mediated inhibitory tone that creates the physiological GH pulse pattern. This is significant for combination research with ipamorelin, as it suggests that GHRH receptor stimulation (by CJC-1295) and ghrelin receptor stimulation (by ipamorelin) can work additively within the context of physiological GH regulation rather than producing supraphysiological, non-pulsatile GH release.
Citation: Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702. PubMed PMID: 17018654
Ipamorelin: Selective GH Release Through the Ghrelin Receptor
The complementary mechanism of ipamorelin was established in the foundational 1998 publication in the European Journal of Endocrinology. Ipamorelin was demonstrated to be the first growth hormone secretagogue that selectively released GH without concurrent elevation of cortisol, ACTH, prolactin, or other pituitary hormones. In swine models, ipamorelin produced GH release comparable to GHRP-6 but with a uniquely clean hormonal profile.
This selectivity is particularly relevant to the CJC-1295 + Ipamorelin combination. GHRH analogs like CJC-1295 stimulate somatotrophs through the GHRH receptor (which uses cAMP signaling), while ipamorelin stimulates them through the GHS-R1a receptor (which uses IP3/calcium signaling). These two intracellular signaling pathways converge on GH vesicle exocytosis through distinct mechanisms, providing the rationale for additive effects when both receptors are engaged simultaneously.
Citation: Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PubMed PMID: 9849822
Growth Hormone Secretagogues: Mechanism of Action Review
A 2020 review in JCSM Rapid Communications provided a comprehensive examination of the history, mechanism of action, and clinical development of growth hormone secretagogues, contextualizing the scientific rationale for combining GHRH analogs with ghrelin receptor agonists. The review detailed how the two receptor systems represent parallel but converging pathways for somatotroph activation.
The review explained that GHRH receptor activation primarily increases cAMP and protein kinase A (PKA) activity in somatotrophs, while GHS-R1a activation by compounds like ipamorelin primarily increases intracellular calcium through phospholipase C signaling. The convergence of these two pathways on GH vesicle release provides a mechanistic basis for the additive effects observed when both pathways are stimulated simultaneously. The review also noted that somatostatin inhibits GH release through both pathways, maintaining the physiological GH pulse pattern even during dual stimulation.
Citation: Ishida J, Taylor MC, Findlay MP, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. doi:10.1002/rco2.9. PubMed PMID: 33225115
Prolonged GH Stimulation and IGF-I Dose-Response Relationships
A study published in the Journal of Clinical Endocrinology & Metabolism (2006) characterized the dose-response relationship of CJC-1295 on GH and IGF-I secretion, providing critical pharmacological data for understanding the GHRH-receptor component of the combination. Subcutaneous CJC-1295 at doses of 30 or 60 μg/kg produced sustained GH elevation with corresponding increases in IGF-I levels.
The dose-response data showed that GH elevations persisted for up to 6 days following a single injection of the DAC-conjugated form, while the non-DAC form (Modified GRF 1-29) produced shorter, pulsatile responses more suitable for mimicking physiological GH secretion patterns. IGF-I elevations followed the GH increases with the expected temporal delay, confirming that the secreted GH was biologically active and capable of stimulating hepatic IGF-I production through the normal GH signaling cascade.
Citation: Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PubMed PMID: 16352683
Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.